(PharmaNewsWire.Com, October 09, 2020 ) The trauma products market is projected to reach USD 7.6 billion by 2025 from USD 5.0 billion in 2020, at a CAGR of 8.3% during the forecast period. The growth in this market is driven by the rising prevalence of degenerative bone diseases, increasing incidence of sports injuries, and the growing number of road accidents and falls. However, Metal sensitivity in patients with trauma implants has hampered market growth to an extent.
The prominent players operating in this market include Acumed LLC (US), Arthrex Inc. (US), B. Braun Melsungen AG (Germany), Citieffe s.r.l. (Italy), CONMED Corporation (US), DePuy Synthes (US), Double Medical Inc. (China), Integra LifeSciences Corporation (US), Orthofix Holdings Inc. (US), Smith & Nephew (UK), Stryker (US), Wright Medical Group N.V. (US), BioPro (US), OsteoMed (US), AGOMED (Germany), NEOORTHO (Brazil), Response Ortho (Turkey), Ortosintese (Brazil), Traumédica (Brazil), and Zimmer Biomet (US). These players adopted the strategies of product launch, expansion, partnerships, agreements, and acquisitions to expand their presence in the global trauma products market.
DePuy Synthes (US) leading position in this market can largely be attributed to its wide range of trauma products. A majority of the company’s sales are generated from the US, and only 40% of its sales are generated outside of the US. The company could focus on expanding its presence and generating revenue from other geographical regions.
Stryker Corporation (US) leading player of the trauma products market in 2019. Its strong brand recognition, extensive product portfolio, and strong geographical presence provide it an edge over its competitors in the trauma products market. In order to maintain its leading position, the company focuses on research and development activities. In 2019, the company invested USD 0.97 billion on R&D activities. The company also focuses on inorganic growth strategies like acquisitions.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
